AC
ABUS icon

AXQ Capital’s Arbutus Biopharma ABUS Stock Holding History

AXQ Capital’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120K Buy
+25,055
New +$110K 0.01% 800
2025
Q3 		– Sell
-18,545
Closed -$57.3K – 554
2025
Q2 		$57.3K Buy
+18,545
New +$61.6K 0.02% 538

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AXQ Capital's ABUS Position: Q2 2026 in Review

AXQ Capital opened a new position in Arbutus Biopharma (ABUS) in Q2 2026: 25,055 shares worth $120K. The stake represents 0.01% of the portfolio and ranks #800 among its holdings. This is a return to the name: AXQ Capital previously reported a position in ABUS as recently as Q2 2025.

AXQ Capital first reported a position in ABUS in Q2 2025 and has held it in 2 quarters since. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • AXQ Capital held 25,055 shares of Arbutus Biopharma worth $120K as of Q2 2026.
  • Arbutus Biopharma was a new AXQ Capital position in Q2 2026.
  • Arbutus Biopharma made up 0.01% of AXQ Capital's portfolio in Q2 2026, its #800 holding.
  • AXQ Capital first reported a position in Arbutus Biopharma in Q2 2025 and has held it in 2 quarters since.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.